{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-006346","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2024-02-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.184981+00:00","generated_at":"2026-06-05T19:43:16.841285+00:00","sec_items":["1.01","2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Vir Biotech Q4/FY2023 net loss $116M/$615M; GSK flu pact ended; cash $1.63B","bullets":["Q4 net loss $116.0M ($0.86 loss per share); FY2023 net loss $615.1M ($4.59 loss per share).","Q4 revenue $16.8M (down 66% YoY); FY revenue $86.2M (down 95% YoY) on lower sotrovimab sales.","Cash, cash equivalents and investments $1.63B as of Dec 31, 2023, down $108M in Q4.","GSK influenza collaboration terminated; Vir retains sole rights to VIR-2482, VIR-2981 and pays low single-digit royalties.","CMO Phil Pang steps down March 31, 2024; SOLSTICE hepatitis delta trial enrollment ahead of schedule with initial data expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-006346","json":"https://secwatch.observer/filing/0001628280-24-006346.json","markdown":"https://secwatch.observer/filing/0001628280-24-006346.md","text":"https://secwatch.observer/filing/0001628280-24-006346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/vir-20240221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T19:43:16.841285+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0c8ad2506c884893236a961e05da69d905892d8","claim":"Vir Biotechnology, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On February 22, 2024, the Company issued a press release announcing its financial results for the fourth quarter and the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b67098706f3dcd498a25194f93db4069f0079453","claim":"Vir Biotechnology, Inc. terminated Letter Agreement with Glaxo Wellcome UK Limited (effective 2024-02-21).","evidence_excerpt":"On February 21, 2024, the Parties entered into a letter agreement (the “Letter Agreement”) pursuant to which the Parties mutually agreed to terminate their collaboration on the Influenza Program under the DCA.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000162828024006346/0001628280-24-006346-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Glaxo Wellcome UK Limited"},{"label":"Effective","value":"2024-02-21"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}